Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

The Lancet Gastroenterology and Hepatology

Volumn 3, Issue 11, 2018, Pages 754-767

  Hajarizadeh, Behzad ^a   Cunningham, Evan B ^a   Reid, Hannah ^a   Law, Matthew ^a   Dore, Gregory J ^a   Grebely, Jason ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PROTEINASE INHIBITOR; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BIBLIOGRAPHIC DATABASE; DISEASE TRANSMISSION; DRUG USE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; META ANALYSIS (TOPIC); NEWCASTLE-OTTAWA SCALE; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RISK ASSESSMENT; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC HEPATITIS C; COMPLICATION; META ANALYSIS; OPIATE ADDICTION; SUBSTANCE ABUSE; SUSTAINED VIROLOGIC RESPONSE;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE, INTRAVENOUS; SUSTAINED VIROLOGIC RESPONSE;

EID: 85055043214     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(18)30304-2     Document Type: Article

References (71)

1. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
2. Grebely, J, Lamey, S, Peacock, A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2018 published online June 23. DOI:10.1111/add.14393.
3. WHO. Global hepatitis report 2017. 2017, WHO, Geneva.
4. Wiessing, L, Ferri, M, Grady, B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One, 9, 2014, e103345.
5. Hagan, H, Pouget, ER, Des Jarlais, DC, Lelutiu-Weinberger, C, Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 168 (2008), 1099–1109.
6. Page, K, Morris, MD, Hahn, JA, Maher, L, Prins, M, Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 57:suppl 2 (2013), S32–S38.
7. Morris, MD, Shiboski, S, Bruneau, J, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis 64 (2017), 860–869.
8. Larney, S, Grebely, J, Hickman, M, et al. Defining populations and injecting parameters among people who inject drugs: implications for the assessment of hepatitis C treatment programs. Int J Drug Policy 26 (2015), 950–957.
9. Degenhardt, L, Peacock, A, Colledge, S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 5 (2017), e1192–e1207.
10. Dore, GJ, Altice, F, Litwin, AH, et al. Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Int Med 165 (2016), 625–634.
11. Grebely, J, Mauss, S, Brown, A, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis 63 (2016), 1405–1411.
12. Lalezari, J, Sullivan, JG, Varunok, P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 63 (2015), 364–369.
13. Grebely, J, Dore, GJ, Zeuzem, S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis 63 (2016), 1479–1481.
14. Grebely, J, Hajarizadeh, B, Dore, GJ, Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol 14 (2017), 641–651.
15. Martinello, M, Dore, GJ, Interferon-free hepatitis C treatment efficacy from clinical trials will translate to “real world” outcomes. Clin Infect Dis 62 (2016), 927–928.
16. Asher, AK, Portillo, CJ, Cooper, BA, et al. Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse 51 (2016), 1218–1223.
17. Wells, G, Shea, B, O'Connell, D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. (Accessed 23 July 2018)
18. Higgins, JPT, Thompson, SG, Deeks, JJ, Altman, DG, Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
19. WHO. Clinical trials. http://www.who.int/topics/clinical_trials/en/. (Accessed 1 August 2018)
20. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 151 (2009), 264–269.
21. Ahmed, OF, Thomson, E, Datta, S, et al. Efficacy of sofosbuvir/ledipasvir in treating genotype 1 and 4 hepatitis C for 8/12 weeks: results from a difficult to treat cohort. J Hepatol, 64, 2016, S805 (abstract SAT-232).
22. Grebely, J, Jacobson, IM, Kayali, Z, et al. SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy. J Hepatol 66 (2017), S513–S514 (abstract FRI-235).
23. Macias J, Morano-Amado LE, Cuenca-Lopez F, et al. High efficacy of IFN-free anti-HCV regimens for individuals on opiate agonist therapy. Conference on Retroviruses and Opportunistic Infections; Seattle WA, USA; Feb 13–16, 2017.
24. Manolakopoulos S, Anagnostou A, Tsirogianni E, et al. Direct acting antiviral (DAA) therapy in people who inject drugs (PWID) with advanced liver disease due to chronic hepatitis c virus (HCV) infection. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
25. Mason, K, Dodd, Z, Guyton, M, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 47 (2017), 202–208.
26. Milne R, Drost A, Grebely J, Selfridge M, Fraser C. DAA therapy for HCV infection among people with a substance use history attending an inner-city community health centre—Victoria, Canada. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
27. Morris, L, Smirnov, A, Kvassay, A, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: findings from the Queensland Injectors' Health Network. Int J Drug Policy 47 (2017), 216–220.
28. Nouch, S, Gallagher, L, Erickson, M, et al. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. Int J Drug Policy 59 (2018), 76–84.
29. O'Sullivan, M, Jones, A-M, Williams, H, Verma, S, Project ITTREAT (Integrated Community Based Test – stage-TREAT HCV Service) for people who inject drugs: year 3 results. Hepatology, 66, 2017, 532A-A (abstract 994).
30. Read, P, Lothian, R, Chronister, K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 47 (2017), 209–215.
31. Scherz, N, Brunner, N, Bruggmann, P, Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data. J Hepatol, 66, 2017, S726-S (abstract SAT-245).
32. Alimohammadi, A, Holeksa, J, Thiam, A, Truong, D, Conway, B, Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs (PWID) delivered in a multidisciplinary setting. Open Forum Infect Dis, 5, 2018 DOI:10.1093/ofid/ofy120.
33. Bielen, R, Moreno, C, Van Vlierberghe, H, et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend 177 (2017), 214–220.
34. Boglione, L, Mornese Pinna, S, De Nicolò A, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepatitis 24 (2017), 850–857.
35. Bouscaillou, J, Kikvidze, T, Butsashvili, M, et al. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia. J Hepatol, 66, 2017, S409-S (abstract FRI-467).
36. Conway B, Grebely J, Fraser C, et al. Paritaprevir/ritonavir/ombitasvir, dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving OST: the D3FEAT study. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
37. Eckhardt, BJ, Scherer, M, Winkelstein, E, Marks, K, Edlin, BR, Hepatitis C treatment outcomes for people who inject drugs treated in an Accessible Care Program located at a syringe service program. Open Forum Infect Dis, 5, 2018, ofy048.
38. Finessi V, Borojevic M, Messina P, et al. Models of care for the management of hepatitis C among people who inject drugs in southern Switzerland: role of nurses. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
39. Grebely, J, Dalgard, O, Conway, B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol 3 (2018), 153–161.
40. Grebely J, Dore GJ, Alami NN, et al. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
41. Litwin AH, Agyemang L, Akiyama M, et al. High rates of sustained virological response in people who inject drugs treated with all-oral direct acting antiviral regimens. 5th International Symposium on Hepatitis Care in Substance Users; Oslo, Norway; Sept 7–9, 2016.
42. Mazhnaya, A, Meteliuk, A, Barnard, T, et al. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: an evaluation of programmatic and treatment outcomes. Int J Drug Policy 47 (2017), 187–195.
43. Norton, BL, Fleming, J, Bachhuber, MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 47 (2017), 196–201.
44. Schütz, A, Moser, S, Schwanke, C, et al. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals. J Viral Hepatitis 25 (2018), 870–873.
45. Valencia, JA, Cuevas, G, Troya, J, et al. HCV therapy as part of an interdisciplinary low-threshold harm reduction strategy in HCV infected injection drug users. Hepatology, 66, 2017, 616A-A (abstract 1145).
46. Boyle A, Marra F, Fox R, et al. Successful treatment of patients on opiate replacement therapy utilising partial directly observed therapy of DAAs in community pharmacies. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
47. Butner, JL, Gupta, N, Fabian, C, Henry, S, Shi, JM, Tetrault, JM, Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abuse Treat 75 (2017), 49–53.
48. Christensen, S, Buggisch, P, Mauss, S, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice?. Addiction 113 (2018), 868–882.
49. Dillon J, Mauss S, Nalpas C, et al. Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
50. Grebley, J, Puoti, M, Wedemeyer, H, et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. J Hepatol, 66, 2017, S514-S (abstract FRI-234).
51. Litwin, AH, Agyemang, L, Akiyama, MJ, et al. The PREVAIL study: intensive models of HCV care for people who inject drugs. J Hepatol, 66, 2017, S72-S (abstract PS-130).
52. Øvrehus, ALH, Krarup, H, Birkemose, I, et al. Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial. J Hepatol 68 (2018), 840–842.
53. Talal, AH, Chen, Y, Andrews, P, et al. Telemedicine-based hepatitis C virus (HCV) management for individuals on opioid agonist treatment (OAT). Hepatology 66 (2017), 624A–625A (abstract 1162).
54. Valente R, Sousa M, Nunes J, Gomes C, Gouveia C, Ferreira A. Hepatitis C treatment in people receiving opioid substitution therapy a difficult population? 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
55. Xynotroulas I, Anagnostou O, Frontzou D, Delistathi A, Tsiaka G. DAAs show very high efficacy in IDUs with chronic hepatitis C, receiving opioid replacement with buprenorphine in central Greece. 6th International Symposium on Hepatitis Care in Substance Users; Jersey City, NY, USA; Sept 6–8, 2017.
56. Afdhal, N, Zeuzem, S, Kwo, P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
57. Feld, JJ, Jacobson, IM, Hézode, C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
58. Foster, GR, Afdhal, N, Roberts, SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
59. Zeuzem, S, Foster, GR, Wang, S, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378 (2018), 354–369.
60. Calleja, JL, Crespo, J, Rincón, D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real world cohort. J Hepatol 66 (2017), 1138–1148.
61. Ioannou, GN, Beste, LA, Chang, MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 151 (2016), 457–471.
62. Tapper, EB, Bacon, BR, Curry, MP, et al. Real-world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study. J Viral Hepatitis 24 (2017), 22–27.
63. Terrault, NA, Zeuzem, S, Di Bisceglie, AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 151 (2016), 1131–1140.
64. Welzel, TM, Hinrichsen, H, Sarrazin, C, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepatitis 24 (2017), 840–849.
65. Marshall, AD, Cunningham, EB, Nielsen, S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol 3 (2018), 125–133.
66. Barua, S, Greenwald, R, Grebely, J, Dore, GJ, Swan, T, Taylor, LE, Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Int Med 163 (2015), 215–223.
67. Zhou, K, Fitzpatrick, T, Walsh, N, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis 16 (2016), 1409–1422.
68. Bajis, S, Dore, GJ, Hajarizadeh, B, et al. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy 47:suppl C (2017), 34–46.
69. Hajarizadeh, B, Grebely, J, Martinello, M, et al. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol 1 (2016), 317–327.
70. Martin, NK, Vickerman, P, Grebely, J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
71. Martin, NK, Vickerman, P, Dore, GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 65 (2016), 17–25.